Articles by Johannes G. Khinast - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Johannes G. Khinast

Johannes G. Khinast


Johannes G. Khinast is a professor at the Graz University in Austria and Head of the Institute of Process and Particle Engineering Scientific Director Research Center Pharmaceutical Engineering (RCPE).

Articles
Comparing Manufacturing Process Options
August 2, 2014

A techno-economic profiling method supports pharmaceutical process development by helping identify the best manufacturing approach.

Peer Reviewed: Numerical Simulation of Tablet Coating
September 2, 2012

The authors investigate the tablet-coating process using a combination of different simulation techniques.

Printable Medicines: A Microdosing Device For Producing Personalized Medicines
January 7, 2011

The authors describe a new method for the production of personalised medicines utilising ultra-precise microdrop printing technology.

Effect of Droplet-Wake Phenomena on Mixing-Sensitive Pharmaceutical Reactions
November 2, 2006

Understanding the impact of reactive mass transfer and local flow in multiphase systems is crucial for maximizing reaction selectivity and minimizing the formation of byproducts. The authors study the influence of mixing on fast liquid–liquid reactions. The iodination of L-tyrosine was used to demonstrate the relationship of droplet size and shape on reaction selectivity and to verify computational predictions. By understanding that droplet dynamics affect the yield and selectivity of fast reactions, the formation of byproducts can be minimized by optimizing operating parameters.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here